Capricor Therapeutics Inc美股招股说明书(2025-12-05版)

TO PROSPECTUS DATED SEPTEMBER 23, 2025 This Prospectus Supplement No. 1 supplements and amends the prospectus dated September 23, 2025(the“Prospectus”), covering the offering, issuance and sale of up to a maximum aggregate offering amountof $150,000,000 (the “Maximum Offering Amount”) of our common stock, par value $0.001 per share Effective as of December 5, 2025, we have reduced the Maximum Offering Amount to $125,000,000. Asof the date of this prospectus supplement, 2,682,307 shares of our Common Stock have been sold underthe ATM Facility, for aggregate gross proceeds of approximately $77.5 million, before deducting sales You should read this prospectus supplement, together with additional information described under theheadings “Information Incorporated by Reference” and “Where You Can Find More Information” in the Investing in our securities involves a high degree of risk. Before making any investment in our securities,you should consider carefully the risks and uncertainties described in the section entitled “Risk Factors” The date of this prospectus supplement is December 5, 2025.